Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC

December 17th 2023

Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.

Advances in Neoadjuvant Immunotherapy for NSCLC: Conference Highlights 2023

December 15th 2023

Dr. Eduardo Santos, MD, FACP, FCCP, highlights advancements in neoadjuvant immunotherapy for NSCLC presented during key conferences in 2023, underscoring pivotal findings and the potential transformation of treatment approaches.

Immunotherapy-Based Strategies for NSCLC in the Neoadjuvant/Perioperative Setting

December 15th 2023

Dr. Eduardo Santos, MD, FACP, FCCP, provides and overview of immunotherapy-based treatment strategies for NSCLC in the neoadjuvant and perioperative setting.

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

December 15th 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

December 15th 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

FDA Grants Priority Review to Tarlatamab for Small Cell Lung Cancer

December 14th 2023

The FDA has accepted and granted priority review to the biologics license application seeking the approval of tarlatamab for the treatment of patients with advanced small cell lung cancer.

Disease Progression Beyond Frontline KRAS G12C Inhibitors

December 14th 2023

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

December 14th 2023

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

December 13th 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights

December 13th 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Advancements in Targeted Therapy for Metastatic NSCLC

December 11th 2023

Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.

Metastatic NSCLC: Key Challenges in Molecular Testing and Treatment Access

December 11th 2023

Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.

Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility

December 8th 2023

The phase 3 KEYLYNK-008 trial evaluating pembrolizumab plus olaparib in patients with metastatic squamous non–small cell lung cancer will be discontinued for futility, according to an announcement from Merck.

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

December 7th 2023

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

December 7th 2023

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

December 6th 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

December 6th 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6th 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Navigating Uncommon Mutations in NSCLC Treatment Decisions

December 6th 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

State of Science Summit: Lung Cancer - Chaired by Ranee Mehra, MD

December 6th 2023

State of Science Summit: Lung Cancer - Chaired by Ranee Mehra, MD

NEXT PAGE
PREVIOUS PAGE